RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR)
A randomised, phase 3 study
Motzer, R., Porta, C., Alekseev, B., Rha, S. Y., Choueiri, T. K., Mendez-vidal, M. J., Hong, S., Kapoor, A., Goh, J. C., Eto, M., Bennett, L., Wang, J., Pan, J. J., Saretsky, T. L., Perini, R. F., He, C. S., Mody, K., & Cella, D. (2022). Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): A randomised, phase 3 study. The Lancet Oncology, 23(6), 768-780. https://doi.org/10.1016/S1470-2045(22)00212-1